Diversified Trust Co cut its stake in Edwards Lifesciences Corp. (NYSE:EW) by 6.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,554 shares of the medical research company’s stock after selling 1,375 shares during the period. Diversified Trust Co’s holdings in Edwards Lifesciences Corp. were worth $2,050,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Legal & General Group Plc raised its position in Edwards Lifesciences Corp. by 2.4% in the first quarter. Legal & General Group Plc now owns 938,532 shares of the medical research company’s stock valued at $82,789,000 after buying an additional 21,672 shares during the last quarter. MIG Capital LLC acquired a new position in Edwards Lifesciences Corp. during the first quarter valued at about $201,000. Nomura Asset Management Co. Ltd. raised its position in Edwards Lifesciences Corp. by 105.3% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 22,560 shares of the medical research company’s stock valued at $1,782,000 after buying an additional 11,570 shares during the last quarter. Mn Services Vermogensbeheer B.V. acquired a new position in Edwards Lifesciences Corp. during the first quarter valued at about $417,000. Finally, UBS Group AG raised its position in Edwards Lifesciences Corp. by 0.6% in the first quarter. UBS Group AG now owns 423,711 shares of the medical research company’s stock valued at $37,375,000 after buying an additional 2,432 shares during the last quarter. Institutional investors and hedge funds own 84.09% of the company’s stock.

Shares of Edwards Lifesciences Corp. (NYSE:EW) traded up 1.43% during mid-day trading on Thursday, reaching $120.87. 1,436,302 shares of the company’s stock traded hands. Edwards Lifesciences Corp. has a 12-month low of $66.57 and a 12-month high of $121.58. The company’s 50 day moving average is $115.27 and its 200 day moving average is $104.45. The company has a market cap of $25.73 billion, a P/E ratio of 49.95 and a beta of 0.60.

Edwards Lifesciences Corp. (NYSE:EW) last released its quarterly earnings data on Tuesday, July 26th. The medical research company reported $0.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.06. The firm had revenue of $759.30 million for the quarter, compared to analyst estimates of $724.26 million. Edwards Lifesciences Corp. had a net margin of 19.26% and a return on equity of 23.72%. The business’s quarterly revenue was up 23.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.57 earnings per share. On average, analysts predict that Edwards Lifesciences Corp. will post $2.88 EPS for the current fiscal year.

Several equities analysts have recently issued reports on the stock. Morgan Stanley lifted their target price on shares of Edwards Lifesciences Corp. from $110.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, July 27th. Deutsche Bank AG lifted their target price on shares of Edwards Lifesciences Corp. from $100.00 to $115.00 and gave the company a “hold” rating in a report on Wednesday, July 27th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $130.00 target price on shares of Edwards Lifesciences Corp. in a report on Thursday, July 28th. Zacks Investment Research lowered shares of Edwards Lifesciences Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Finally, Canaccord Genuity lifted their target price on shares of Edwards Lifesciences Corp. from $132.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, July 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $118.13.

In related news, CEO Michael A. Mussallem sold 49,100 shares of the firm’s stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $113.31, for a total transaction of $5,563,521.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 18,000 shares of the firm’s stock in a transaction on Friday, September 2nd. The shares were sold at an average price of $115.78, for a total transaction of $2,084,040.00. The disclosure for this sale can be found here. 2.37% of the stock is currently owned by insiders.

About Edwards Lifesciences Corp.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp. (NYSE:EW).

Receive News & Ratings for Edwards Lifesciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.